論文

査読有り 国際誌
2017年10月

Progressive Hypofractionated Carbon-Ion Radiotherapy for Hepatocellular Carcinoma: Combined Analyses of 2 Prospective Trials

CANCER
  • Goro Kasuya
  • Hirotoshi Kato
  • Shigeo Yasuda
  • Hiroshi Tsuji
  • Shigeru Yamada
  • Yasuo Haruyama
  • Gen Kobashi
  • Daniel K. Ebner
  • Naomi Nagatake Okada
  • Hirokazu Makishima
  • Masaru Miyazaki
  • Tadashi Kamada
  • Hirohiko Tsujii
  • 全て表示

123
20
開始ページ
3955
終了ページ
3965
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1002/cncr.30816
出版者・発行元
WILEY

BACKGROUND: The objective of this study was to evaluate the safety and efficacy of carbon-ion radiotherapy (CIRT) in patients with hepatocellular carcinoma (HCC) with stepwise dose escalation and hypofractionation in 2 combined prospective trials. METHODS: Sequential phase 1/2 (protocol 9603) and phase 2 (protocol 0004) trials were conducted for patients with histologically proven HCC. The phase 1 component of protocol 9603 was a dose-escalation study; CIRT was delivered in 12, 8, or 4 fractions. After determination of the recommended dose, 2 phase 2 trials were performed in an expanded cohort, and the data were pooled to analyze toxicity, local control, and overall survival. RESULTS: In the phase 1 component of protocol 9603, 69.6, 58.0, and 52.8 Gy (relative biological effectiveness [RBE]) in 12, 8, and 4 fractions, respectively, constituted the maximum tolerated doses, and 52.8 Gy (RBE) in 4 fractions was established as the recommended dose regimen for the 2 phase 2 studies. In 124 patients with a total of 133 lesions, few severe adverse effects occurred, and local-control and overall survival rates at 1, 3, and 5 years were 94.7% and 90.3%, 91.4% and 50.0%, and 90.0% and 25.0%, respectively; this included 1-, 3-, and 5-year local-control rates of 97.8%, 95.5%, and 91.6%, respectively, in the phase 2 study. In a multivariate analysis, Child-Pugh class B and the presence of a tumor thrombus were significant factors for mortality. CONCLUSIONS: The safety and efficacy of CIRT in 12, 8, and 4 fractions were confirmed, with 52.8 Gy (RBE) in 4 fractions established as the recommended treatment course for eligible HCC patients. Cancer 2017; 123: 3955-65. VC 2017 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

リンク情報
DOI
https://doi.org/10.1002/cncr.30816
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/28662297
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000412138700014&DestApp=WOS_CPL
ID情報
  • DOI : 10.1002/cncr.30816
  • ISSN : 0008-543X
  • eISSN : 1097-0142
  • PubMed ID : 28662297
  • Web of Science ID : WOS:000412138700014

エクスポート
BibTeX RIS